Innovation in Cardio-Renal-Metabolic Diseases
Research into cardio-renal-metabolic diseases is at a turning point. Advances in treatment and an enhanced emphasis on primary prevention have resulted in significant improvements in life expectancy over the last 30 years. Yet challenges remain. Worldwide obesity has nearly tripled since 1975, with nearly 2 billion adults considered overweight (BMI ≥ 25 kg/m2) in 20161), of which 650 million are considered having obesity (BMI ≥ 30 kg/m2). The rising rates of obesity promote the worldwide prevalence of associated diseases, such as type 2 diabetes, non-alcoholic steatohepatitis (NASH) and cardiovascular diseases. Our deep scientific expertise and long history of innovation across the cardio-renal-metabolic spectrum give us a unique perspective in addressing these challenges.
Global Head of CardioMetabolic Diseases Research,
Boehringer Ingelheim
“We are currently focusing our preclinical research on diseases with a high unmet need such as obesity and liver diseases. We are building on our deep scientific expertise that encompasses a broad range of cardio-renal-metabolic disease pathomechanisms and blending this with the skills and knowledge of external partners across the life-science community and by leveraging open science, as we strive to create first-in-class therapeutics. Together, our goal is to discover and develop breakthrough medicines that will transform the lives of patients now and in generations to come.”
The Big Picture: A Holistic Approach to CardioMetabolic Disease Research
Facing the challenging landscape, Boehringer Ingelheim’s cardiometabolic research strategy takes a holistic view of the broader therapeutic needs of patients who may often have multiple conditions, connected by underlying similar pathologies.
With a very strong focus on developing a deep understanding of the human disease, we are working on identifying new innovative therapeutic concepts. We are building on our traditional strengths in molecular biology, pharmacology, and medicine, and complementing them with novel approaches, based on a broader access to patients’ biobanks and on new digital tools to support the analysis of such large data bases. By exploring disease mechanisms and common pathways within various cardiometabolic diseases, we aim to leverage synergies in our pursuit of identifying the next wave of innovative medicines. Our efforts are supported through collaborations with leading investigators across the globe.